Pharmacogenomics in Psychiatry: Implications for Practice

Title:Pharmacogenomics in Psychiatry: Implications for Practice

Volume: 8 Issue: 2

Author(s): Thea R. Moore, Angela M. Hill and Siva K. Panguluri

Affiliation:

Keywords: Agranulocytosis, antidepressants, antipsychotics, anxiolytics, aripiprazole, clozapine, cytochrome P450, dopamine receptor gene, human leukocyte antigen, isoenzymes, metabolic syndrome, mood stabilizers, polymorphisms, psychotropic, risperidone, serotonin.

Abstract: Psychotropic medications are used for numerous psychiatric and neurologic disorders, and are associated with in some cases life-threatening adverse effects, high acquisition costs, stringent monitoring requirements, and potential interactions with other medications. Because of the risks of adverse effects and need for adherence, risk mitigation strategies are being implemented to protect consumers. An understanding of receptor activities, cytochrome P450 2D6 and 2C19 metabolism, overlapping pharmacology, and polymorphic biomarkers for the dopamine 2 D2 receptor gene (DRD2) and dopamine 3 D3 receptor gene (DRD3), serotonin 2A and 2C receptor genes (5HTR2A and 5HTR2C), and human leukocyte antigen (HLA) variants creates opportunities for the integration of pharmacogenomics, and can assist in the application of personalized medicine in this arena. In this review, we discuss the current impression of pharmacogenomic principles pertaining to select psychotropics, with attention given to the atypical antipsychotics, due to their wide use across a broad spectrum of psychiatric disorders (e.g. bipolar disorder, depression, schizophrenia). Patents involving aripiprazole, clozapine, olanzapine, and risperidone will be discussed.

Cite this article as:

Moore R. Thea, Hill M. Angela and Panguluri K. Siva, Pharmacogenomics in Psychiatry: Implications for Practice, Recent Patents on Biotechnology 2014; 8 (2) . https://dx.doi.org/10.2174/1872208309666140904113615